跳至主要内容
临床试验/TCTR20220404001
TCTR20220404001尚未招募4 期

A randomized control trial comparing the antibodies to COVID-19 vaccine between kidney transplant recipients who continue on immunosuppressive regimen of tacrolimus and mycophenolic acid and recipients who switch to mTOR inhibitor with low dose tacrolimus two weeks before vaccination

Division of nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University0 个研究点目标入组 40 人开始时间: 2022年4月4日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • 1. Age >= 18
  • 2. Kidney transplant > 6 months
  • 3. Receiving MPA and CNI
  • 4. Received 2 doses of ChAdOx1 nCoV-19 and 1 dose of BNT162b2 for 3-5 months

排除标准

  • 1. History of severe allergy from BNT162b2
  • 2. Rejection within 6 months
  • 3. High risk for rejection : ABO incompatible, multiorgan transplantation, previous transplantation, recent panel reactive antibody (PRA) > 20% or donor specific antibody (DSA) positive
  • 4. Pregnancy or lactation
  • 5. Advanced stage cancer

研究者

发起方
Division of nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University

相似试验